Evaluating Impurities in Drugs (Part III of III) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Impurities in Drugs (Part III of III)
In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 76-86

Impurity profiling

Ideally, an impurity profile should show all impurities in a single format to allow monitoring of any variation in the profile. The driving forces for studying an impurity profile are quality considerations and regulatory requirements.

Samples to be profiled . Impurity profiling should be done for APIs, process check of the synthesis or formulation, and final drug product.

Components in an impurity profile. Ideally, an impurity profile should show synthesis-related impurities, formulation-related impurities, degradation products, and interaction products.

Crucial factors for controlling impurities in API s. Several factors are important in controlling impurities in APIs as further outlined.

Crystallization . The size of crystals not only determines the quality, but also the stability of the drug. During crystallization, fine crystals should be formed to prevent entrapment of minute amounts of chemicals from the mother liquor, which in turn causes degradation of the drug.

Wet-cake washing. Many unwanted chemicals, including residual solvents, could be removed by thorough washing of the wet cake, which if not done correctly, could lead to retention of solvents and impurities in the cake.

Drying. Use of vacuum dryer or a fluid-bed dryer is always advisable in comparison to a tray dryer. Use of the former reduces drying time and brings about uniform drying, which is helpful in drying sensitive drug substances.

Appropriate packaging. The packing of bulk drugs should be based upon their nature and sensitivity. Light-sensitive products should be packed in light protective packing. Use of opaque containers for ciprofloxacin eye-drops preparations protects the active ingredients from photodegradation (22). Use of ampuls with either black carbon paper or aluminum foil for ergometrine produced negligible degradation (40). It is important to determine the most appropriate container-closure system.

Production methods based on stability studies . A manufacturer of a bulk drug should perform a detailed investigation of the process, including stability studies while finalizing the method of preparation. For example, for producing diclofenac sodium injections, the aseptic filtration process is better than the autoclave method that produces the impurity (16).

Measures by pharmacopoeias . Pharmacopoeias should take steps to incorporate impurity limits for drug substances made from a raw material in which that particular impurity is controlled. It becomes convenient for the users if the impurity limit is mentioned in the dosage forms.

Conclusion

Parts I, II, and III of this article discussed the types, origin, causes, chemistry, and impact of impurities in APIs and drug products (1, 2). Parts I and II explained how, when, and why impurities are formed. This article, Part III, highlighted the degradation-related, formulation-related, and metabolite impurities, the various analytical techniques available for their identification and separation, and crucial factors that are to be controlled while preparing bulk drugs.

Kashyap R. Wadekar , PhD ,* is a research scientist (II), Ponnaiah Ravi , PhD , is senior vice-president of R&D, Mitali Bhalme , PhD , is an associate research scientist, S. Srinivasa Rao is a research associate, K. Vigneshwar Reddy is a research associate, L. Sampath Kumar is a research chemist, and E. Balasubrahmanyam is a research chemist, all with Neuland Laboratories, 204 Meridian Plaza, 6-3-854/1, Ameerpet, Hyderabad, India, tel. 91 40 30211600,
.

*To whom all correspondence should be addressed.

Submitted: Sept. 19, 2011; Accepted Nov. 28, 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here